J&J Renova Comparative Efficacy Study Among Post-Approval Requirements
This article was originally published in The Rose Sheet
Executive Summary
A comparative efficacy study between newly approved Renova .02% and the currently marketed .05% tretinoin cream formula is among the data commitments requested of marketer Johnson & Johnson's Ortho Dermatological. The new Renova formula will be available by prescription only in November.